Natera, Inc. (NASDAQ:NTRA - Get Free Report) CEO Steven Leonard Chapman sold 6,816 shares of the business's stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $93.13, for a total value of $634,774.08. Following the completion of the transaction, the chief executive officer now directly owns 227,710 shares of the company's stock, valued at approximately $21,206,632.30. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Steven Leonard Chapman also recently made the following trade(s):
- On Thursday, March 28th, Steven Leonard Chapman sold 2,662 shares of Natera stock. The stock was sold at an average price of $90.42, for a total value of $240,698.04.
- On Friday, March 15th, Steven Leonard Chapman sold 83,223 shares of Natera stock. The stock was sold at an average price of $88.96, for a total value of $7,403,518.08.
- On Tuesday, March 5th, Steven Leonard Chapman sold 9,326 shares of Natera stock. The shares were sold at an average price of $88.36, for a total transaction of $824,045.36.
- On Monday, January 29th, Steven Leonard Chapman sold 14,813 shares of Natera stock. The shares were sold at an average price of $65.09, for a total transaction of $964,178.17.
- On Monday, January 22nd, Steven Leonard Chapman sold 1,958 shares of Natera stock. The shares were sold at an average price of $68.16, for a total transaction of $133,457.28.
Natera Price Performance
Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share
From Colonial Metals | Ad
The latest flare-up between Israel and Palestinian militants has sent gold prices surging.
Why? Because savvy investors know the endgame of the elites at play…
Geopolitical crises breed uncertainty — and gold thrives on uncertainty.
See why the elites are pouring billions into gold.
NTRA stock opened at $90.33 on Thursday. Natera, Inc. has a 1-year low of $36.90 and a 1-year high of $98.82. The company has a debt-to-equity ratio of 0.37, a quick ratio of 3.96 and a current ratio of 4.10. The business has a 50 day simple moving average of $85.39 and a two-hundred day simple moving average of $65.41.
Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.09. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. The business had revenue of $311.11 million during the quarter, compared to the consensus estimate of $300.38 million. As a group, equities analysts anticipate that Natera, Inc. will post -2.35 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several equities research analysts have recently commented on the stock. The Goldman Sachs Group upped their price target on shares of Natera from $90.00 to $100.00 and gave the company a "buy" rating in a research report on Monday. Sanford C. Bernstein raised shares of Natera from a "market perform" rating to an "outperform" rating and set a $120.00 price target for the company in a research report on Friday, April 5th. Raymond James lowered shares of Natera from a "strong-buy" rating to an "outperform" rating and upped their price target for the company from $68.00 to $85.00 in a research report on Tuesday, February 20th. BTIG Research upped their price target on shares of Natera from $75.00 to $85.00 and gave the company a "buy" rating in a research report on Friday, December 29th. Finally, Piper Sandler upped their price target on shares of Natera from $70.00 to $110.00 and gave the company an "overweight" rating in a research report on Wednesday, March 6th. One research analyst has rated the stock with a sell rating and fourteen have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $86.40.
Get Our Latest Research Report on Natera
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in NTRA. RiverPark Advisors LLC bought a new position in Natera in the 4th quarter worth approximately $27,000. Principal Securities Inc. bought a new position in shares of Natera during the 4th quarter valued at approximately $32,000. Harvest Fund Management Co. Ltd bought a new position in shares of Natera during the 3rd quarter valued at approximately $44,000. Oliver Lagore Vanvalin Investment Group boosted its position in shares of Natera by 109.3% during the 4th quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company's stock valued at $47,000 after acquiring an additional 389 shares during the last quarter. Finally, CWM LLC boosted its position in shares of Natera by 224.4% during the 3rd quarter. CWM LLC now owns 1,317 shares of the medical research company's stock valued at $58,000 after acquiring an additional 911 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors.
About Natera
(
Get Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
